Tang Peipei, Tan Yong, Yin Yanyun, Nie Xiaowei, Huang Jingyu, Zuo Wenting, Li Yuling
Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, China.
Nan Fang Yi Ke Da Xue Xue Bao. 2025 May 20;45(5):929-941. doi: 10.12122/j.issn.1673-4254.2025.05.05.
To assess the efficacy and safety of (TZZY) recipe for treatment of premature ovarian insufficiency (POI) and explore the possible mechanisms.
We used bioinformatics analyses and network pharmacology to identify the main active ingredients in TZZY recipe and their core targets, which were verified by Western blotting. We tested the efficacy and safety of the recipe in 60 POI patients, who were randomized into control group (=30) with Femoston treatment and TZZY group (=30) with additional TZZY recipe treatment for 3 menstrual cycles.
The core active ingredients of TZZY recipe included kaempferol, β-sitosterol, luteolin, and quercetin. The core targets included , , , , and , which were involved in positive regulation of cell movement and protein phosphorylation, the cancer pathways and the PI3K-Akt signaling pathway. Molecular docking showed that the core active ingredients had good binding ability with the core targets. In female rat models of POI, TZZY recipe treatment significantly up-regulated ovarian expressions of p-PI3K and p-Akt proteins. In the clinical trial, treatment with Femoston and Femoston plus TZZY recipe both significantly increased E levels and reduced FSH and LH levels and Kupperman scores of the patients, and the combined treatment produced significantly stronger effects. Both treatments increased the number of antral follicles of the patients, but the combined treatment also significantly increased the levels of AMH.
The therapeutic mechanism of TZZY recipe for POI involves multiple active ingredients, multiple therapeutic targets and multiple pathways, and activating the PI3K /Akt pathway is one of its main mechanisms of action, to improve ovarian reserve function, alleviate clinical symptoms, and enhance clinical efficacy in POI patients.
评估(天紫滋阴方)治疗卵巢早衰(POI)的疗效和安全性,并探讨其可能机制。
我们采用生物信息学分析和网络药理学来确定天紫滋阴方中的主要活性成分及其核心靶点,并通过蛋白质印迹法进行验证。我们对60例POI患者进行了该方剂的疗效和安全性测试,将患者随机分为对照组(n = 30)接受芬吗通治疗,天紫滋阴方组(n = 30)在芬吗通治疗基础上加用天紫滋阴方治疗3个月经周期。
天紫滋阴方的核心活性成分包括山奈酚、β-谷甾醇、木犀草素和槲皮素。核心靶点包括[具体靶点未给出],它们参与细胞运动的正调控、蛋白质磷酸化、癌症通路和PI3K-Akt信号通路。分子对接显示核心活性成分与核心靶点具有良好的结合能力。在POI雌性大鼠模型中,天紫滋阴方治疗显著上调卵巢中p-PI3K和p-Akt蛋白的表达。在临床试验中,芬吗通治疗以及芬吗通联合天紫滋阴方治疗均显著提高患者的E水平,降低FSH、LH水平和Kupperman评分,联合治疗效果更显著。两种治疗均增加了患者窦卵泡数量,但联合治疗还显著提高了AMH水平。
天紫滋阴方治疗POI的作用机制涉及多种活性成分、多个治疗靶点和多条途径,激活PI3K/Akt途径是其主要作用机制之一,可改善POI患者的卵巢储备功能,缓解临床症状,提高临床疗效。